Palatin Technologies (PTN)
(Delayed Data from AMEX)
$1.80 USD
-0.07 (-3.74%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum D VGM
Brokerage Reports
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 1 - 20 ( 195 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MELODY-1 Data Highlights From ASCRS 2024; Awaiting FDA Meeting in 2Q24 For Regulatory Guidance
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Does MELODY-1 Hit the Right Chord; We''ll See FDA Feedback; Target Lowered to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q24 Results; A Year of Catalysts, But Eyes Are Fixed on Imminent DED Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Bright Pipeline Outlook in 2024; Embracing a Wave of Upcoming Data Updates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
The Vyleesi Climax With Cash For the Effort; Focus on Phase 3 DED Data Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Critical Near-Term Data Catalysts In Our Universe Represent Thesis Definers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F1Q24 Results; Looking For Sweet Music Shortly on Pivotal DED Study Read Out; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Uniting Melanocortin Receptor and GLP-1 Therapies For Obesity and Diabetes
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Further Bolster PL8177''s Potential in UC; Phase 2 UC Interim Data in 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
FY2023 Results; Pivotal DED Data Soon; Vyleesi Continues to Grow
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MELODY-1 Completes Enrollment; Top-Line Data in 4Q23 Represents Major Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Vyleesi Strengthens Foothold in Asian Marketplace; First China Sale and Phase 3 HSDD Enrollment Completed
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
New Partnership With UpScriptHealth Amplifies Vyleesi Access and Awareness
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Targeting Podocytes to Resolve Kidney Injury; Preclinical Data Support MC1r Agonists? Ability to Treat DN
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F3Q23 Results; A Melanocortin Medley of Data Readouts to Come; Reiterate Top Pick
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data Spotlight P8177 in IBD; Phase 2 Top-Line Data in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Recipe for Success; KOL Event Highlights PL9643 and Clinical Strategy Ahead of Full MELODY-1 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
A Sight For Sore Eyes; PL9643 Exhibits Initial Pivotal Promise in DED; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
PL9588 Shows Initial Signs of Efficacy in Glaucoma Models; Vyleesi Traction Grows
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J